CLDN11 and cancer: 11 signaling pathways were further enriched, including hsa04510-Focal adhesion (CLDN11, SMAD4), hsa04512-ECM-receptor interaction (MMP9, ECM1), and hsa05200-pathways in cancer (CLDN11, MTMR14) (Figure 3B).